文献速递肺外科

全胸腔镜主要肺切除术治疗临床I期非小细胞肺癌的肿瘤学结果

Oncological results of full thoracoscopic major pulmonary resections for clinical Stage I non-small-cell lung cancer.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

基于前瞻性意向治疗数据库分析2007年至2016年8月接受全胸腔镜主要肺切除术的非小细胞肺癌患者,648例中621例为临床I期;临床I期患者病理升级占22.5%,N1或N2淋巴结升级占15.8%;全队列5年总生存率75%,临床IA期76%与IB期70.9%有显著差异;肿瘤<2 cm时肺段切除组与肺叶切除组总生存无显著差异(74% vs 78.9%,P=0.634)。结论认为全胸腔镜入路不损害长期生存,结果与视频辅助技术相当。

要点

  • 临床I期患者中22.5%出现病理升级,15.8%出现N1或N2淋巴结升级。
  • 全队列5年总生存率75%,临床IA期76% vs IB期70.9%有显著差异。
  • 肿瘤<2 cm时肺段切除组与肺叶切除组5年总生存无显著差异。

核心结论

  • 全胸腔镜主要肺切除术不损害长期生存,结果与视频辅助技术相当。

研究设计与样本

  • 基于2007年至2016年8月前瞻性意向治疗数据库,纳入接受全胸腔镜主要肺切除术的非小细胞肺癌患者,648例符合标准,其中621例为临床I期。
  • 排除16例寡转移患者和11例cT3或cT4患者后分析临床I期患者。
  • 采用Kaplan-Meier曲线估计总生存和无病生存,log-rank检验比较生存差异。

主要发现

  • 全队列平均随访34.5个月,中转开胸40例(6.3%),30天或住院死亡率为0.95%,并发症发生率29.3%。
  • 临床I期患者中22.5%出现病理升级,15.8%出现N1或N2淋巴结升级。
  • 全队列5年总生存率为75%,临床IA期为76%,临床IB期为70.9%,两者有显著差异。
  • 肿瘤<2 cm时,肺段切除组与肺叶切除组5年总生存率分别为74%和78.9%(P=0.634),无显著差异。

临床怎么用

  • 作者认为全胸腔镜主要肺切除术不损害长期生存,结果与视频辅助技术相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The full thoracoscopic approach to major pulmonary resections is considered challenging and controversial as it might compromise oncological outcomes. The aim of this work was to analyse the results of a full thoracoscopic technique in terms of nodal upstaging and survival in patients with non-small-cell lung carcinoma (NSCLC). METHODS: All patients who underwent a full thoracoscopic major pulmonary resection for NSCLC between 2007 and August 2016 were analysed from an 'intent-to-treat' prospective database. Overall survival and disease-free survival were estimated using the Kaplan-Meier curves and comparisons in survival using the log-rank test. RESULTS: A total of 648 patients met the inclusion criteria, of whom 621 patients had clinical Stage I and 27 had higher stages (16 oligometastatic patients were excluded from the analysis, 11 cT3 or cT4). The mean follow-up was 34.5 months. There were 40 conversions to thoracotomy (6.3%). Thirty-day or in-hospital mortality was 0.95%. Complications occurred in 29.3% of patients. On pathological examination, 22.5% of clinical Stage I patients were upstaged. Nodal upstaging to N1 or N2 was observed in 15.8% of clinical Stage I patients. Five-year overall survival of the whole cohort was 75% and was significantly different between clinical Stages IA (76%) and IB (70.9%). For tumours <2 cm, no significant difference in overall survival was found for the segmentectomy group compared to the lobectomy group: 74% versus 78.9% (P = 0.634). CONCLUSIONS: Long-term survival is not compromised by a full thoracoscopic approach. Our results compared favourably with those of video-assisted techniques.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Lutz JA, Seguin-Givelet A, Grigoroiu M, et al. Oncological results of full thoracoscopic major pulmonary resections for clinical Stage I non-small-cell lung cancer. Eur J Cardiothorac Surg. 2019. PMID: 30052990. doi:10.1093/ejcts/ezy245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。